デフォルト表紙
市場調査レポート
商品コード
1427906

中堅医薬品の世界市場レポート 2024年

Mid-Size Pharmaceuticals Global Market Report 2024

出版日: | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.47円
中堅医薬品の世界市場レポート 2024年
出版日: 2024年02月14日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

中堅医薬品の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.5%の年間複合成長率(CAGR)で9,356億5,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、価値ベースのケアモデルの採用の増加、規制経路の合理化、健康意識の高まりと患者のエンパワーメント、ジェネリック医薬品とバイオシミラー医薬品の需要の高まり、デジタル医薬品の出現など、いくつかの要因に関連している可能性があります。治療薬。予測期間中に予想される注目すべき動向には、患者中心のアプローチの重視の高まり、人工知能(AI)の普及、世界市場拡大戦略、環境の持続可能性に焦点を当てた取り組み、遠隔医療と遠隔患者モニタリングの利用増加などが含まれます。

中堅医薬品市場の予想される成長は、慢性疾患の有病率の増加によって促進されると予想されます。慢性疾患は、継続的な管理と治療を必要とする長期の病状として特徴付けられ、医薬品に対する多大な需要を生み出します。質量分析技術は、これらの慢性疾患に関連するバイオマーカーと代謝産物の特定、定量、分析において重要な役割を果たします。 2023年1月の国立医学図書館のデータで浮き彫りになった慢性疾患有病率の上昇予測は、少なくとも1つの慢性疾患を患う50歳以上の人の数が2020年の7,152万2,000人から大幅に増加していることを示しています。 2050年には1億4,266万人と推定され、99.5%増加します。したがって、慢性疾患の急増が中堅医薬品市場の成長の重要な原動力となっています。

医療への支出の増加は、中規模の医薬品市場の成長に寄与すると予想されます。医療には、全体的な健康を維持と改善するという包括的な目標を持った、医療、予防サービス、診断検査、治療、とサポートサービスの組織的な提供が含まれます。医療支出の増加は、多くの場合、製薬業界内の研究開発への投資の増加につながります。中規模の製薬会社は、この増加した投資から恩恵を受け、新薬を開発して市場に導入できるようになります。たとえば、2022年の経済調査のデータによると、インドの医療への公的支出は2021年から2022年にかけてGDPの2.1%に達しました。さらに、Willis Towers Watson Public Limited Companyが実施した調査では、医療給付費の世界平均増加率が示されており、2022年には8.8%に増加し、2023年にはさらに10%に増加すると予測されています。この医療費の増加は、医療給付費の増加を促進する準備ができています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の中堅医薬品市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の中堅医薬品市場規模実績と成長、2018~2023年
  • 世界の中堅医薬品市場規模と成長予測、2023~2028年、2033年

第6章 市場セグメンテーション

  • 世界の中型医薬品市場、医薬品開発タイプ別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 社内
  • アウトソーシング
  • 世界の中型医薬品市場、タイプ別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 処方薬
  • 店頭薬
  • 世界の中型医薬品市場、製剤別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • タブレット
  • カプセル
  • 注射剤
  • スプレー
  • その他
  • 世界の中型医薬品市場、用途別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 心血管疾患
  • 疼痛管理
  • 糖尿病
  • がん
  • その他

第7章 地域と国の分析

  • 世界の中型医薬品市場、地域別、実績と予測、2018~2023年、2023~2028年、2033年
  • 世界の中型医薬品市場、国別、実績と予測、2018~2023年、2023~2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 中堅医薬品市場の競合情勢
  • 中堅医薬品市場の企業プロファイル
    • Baxter International Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Otsuka Pharmaceutical Co Ltd.
    • Arkema Inc.
    • Astellas Pharma Inc.

第31章 その他の大手と革新的な企業

  • Daiichi Sankyo Co. Ltd.
  • Alexion Pharmaceuticals Inc.
  • UCB SA
  • Sun Pharmaceutical Industries Ltd.
  • Eisai Co. Ltd.
  • Wuxi AppTec co. Ltd.
  • Les Laboratoires Servier SA
  • Hospira Inc.
  • Perrigo Co Plc
  • Aurobindo Pharma Limited.
  • Cipla Limited
  • Hikma Pharmaceuticals
  • Endo International plc
  • Taisho Pharmaceutical Holdings Co. Ltd.
  • BioMarin Pharmaceutical Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r13750

Mid-sized pharmaceutical companies are characterized by annual revenues ranging from $1 billion to $10 billion. These companies engage in diverse activities such as drug development, niche market targeting, regional presence, partnerships, generic drug manufacturing, and contract manufacturing.

The primary modes of drug development for mid-sized pharmaceutical firms include in-house and outsourced approaches. In-house activities refer to functions conducted internally within the organization by its own employees or departments, rather than being outsourced to external parties or contractors. In the context of mid-sized pharmaceuticals, in-house activities encompass a range of functions such as research and development, manufacturing, quality control, regulatory affairs, sales and marketing, and other operational aspects of the pharmaceutical business. These companies typically offer prescription and over-the-counter medications in various forms, including tablets, capsules, injectables, sprays, and others, catering to the treatment of conditions such as cardiovascular diseases, pain management, diabetes, cancer, and more.

The mid-size pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides mid-size pharmaceuticals market statistics, including the mid-size pharmaceuticals industry's global market size, regional shares, competitors with a mid-size pharmaceuticals market share, detailed mid-size pharmaceuticals market segments, market trends, and opportunities, and any further data you may need to thrive in the mid-size pharmaceuticals industry. This mid-size pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mid-size pharmaceuticals market size has grown strongly in recent years. It will grow from $678.75 billion in 2023 to $727.15 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the historical period can be ascribed to several factors, including the expansion of the generic drug market, the expiration of patents for blockbuster drugs, initiatives to contain healthcare costs, the growth of biotechnology, and regulatory changes that foster innovation.

The mid-size pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $935.65 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be linked to several factors, including the increasing adoption of value-based care models, streamlined regulatory pathways, rising health awareness and patient empowerment, a growing demand for generic and biosimilar drugs, and the emergence of digital therapeutics. Noteworthy trends expected in the forecast period encompass a heightened emphasis on patient-centric approaches, the widespread adoption of artificial intelligence (AI), global market expansion strategies, initiatives focused on environmental sustainability, and the increased utilization of telemedicine and remote patient monitoring.

The anticipated growth in the mid-size pharmaceuticals market is expected to be propelled by the increased prevalence of chronic diseases. Chronic diseases, characterized as long-term medical conditions requiring ongoing management and treatment, generate substantial demand for medications. Mass spectrometry techniques play a crucial role in identifying, quantifying, and analyzing biomarkers and metabolites associated with these chronic diseases. The projected rise in the prevalence of chronic diseases, as highlighted by data from the National Library of Medicine in January 2023, indicates a substantial increase in the number of individuals aged 50 and older with at least one chronic disease, from 71.522 million in 2020 to an estimated 142.66 million in 2050-an increase of 99.5%. Consequently, the surge in chronic diseases is a significant driver behind the growth of the mid-size pharmaceuticals market.

The increasing expenditure on healthcare is expected to contribute to the growth of the mid-size pharmaceutical market. Healthcare encompasses the organized provision of medical care, preventive services, diagnostic testing, treatment, and support services, with the overarching goal of maintaining and improving overall health. Higher healthcare spending often translates into increased investment in research and development within the pharmaceutical industry. Mid-sized pharmaceutical companies stand to benefit from this heightened investment, enabling them to develop and introduce new drugs to the market. For example, data from the Economic Survey of 2022 reveals that India's public expenditure on healthcare reached 2.1% of GDP in 2021-22. Furthermore, a survey conducted by Willis Towers Watson Public Limited Company indicates a global average growth in healthcare benefit costs, which increased to 8.8% in 2022 and is projected to further rise to 10% in 2023. This increased healthcare expenditure is poised to drive the growth of the mid-size pharmaceutical market.

Technology advancements stand out as a prominent trend gaining momentum in the mid-size pharmaceuticals market. Leading companies in this market are leveraging technology to maintain their competitive positions. For example, in May 2023, Google Cloud, the suite of cloud computing services offered by Google, introduced A.I.-powered tools aimed at accelerating drug discovery and precision medicine. One such tool, the Target and Lead Identification Suite, assists businesses in anticipating and understanding protein structure, a critical aspect of drug research. Another tool, the Multiomics Suite, enables researchers to ingest, store, analyze, and share large volumes of genetic data.

Major companies in the mid-size pharmaceuticals sector are strategically focusing on product development and launches, particularly in the area of precision medicine platforms, to sustain their market positions. A precision medicine platform is an advanced technology or system designed to customize medical treatment and interventions based on the specific characteristics of individual patients. In February 2023, C4X Discovery Holdings PLC, a mid-size pharmaceutical company based in the UK, unveiled its innovative precision medicine platform, PatientSeek. This platform identifies patients who are most likely to benefit from a specific medication based on their genetic makeup. The launch of PatientSeek follows successful validation in patient stratification, where a subgroup of patients responding positively to treatment was identified during a retrospective analysis of a Phase 3 clinical trial for Parkinson's disease. This development showcases the potential of precision medicine in optimizing treatment outcomes by leveraging genetics for targeted and effective medication strategies.

In March 2023, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Concert Pharmaceuticals for $576 million. This strategic acquisition enables Sun Pharmaceutical Industries Limited to incorporate Concert's innovative medicines, including deuruxolitinib-a novel, deuterated, oral JAK1/2 inhibitor-into its pipeline. Deuruxolitinib holds potential for treating adult patients with moderate to severe alopecia areata, expanding Sun Pharmaceutical's portfolio and strengthening its position in the mid-size pharmaceuticals market. Concert Pharmaceuticals Inc., the acquired entity, is a US-based late-stage clinical mid-sized biopharmaceutical company dedicated to developing innovative medicines with unique therapeutic properties.

Major companies operating in the mid-size pharmaceuticals market report are Baxter International Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Arkema Inc., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Alexion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Wuxi AppTec co. Ltd., Les Laboratoires Servier S.A., Hospira Inc., Perrigo Co PLC, Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals, Endo International PLC, Taisho Pharmaceutical Holdings Co. Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt PLC, Exelixis Inc., Mylan Pharmaceuticals Inc., Neurocrine Biosciences Inc., Kyowa Kirin Co. Ltd., Emergent BioSolutions Inc.

North America was the largest region in the mid-size pharmaceutical market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mid-size pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mid-size pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mid-sized pharmaceuticals market consists of revenues earned by entities providing pharmaceutical services such as drug development, research activities, generic drug manufacturing, and contract manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The mid-sized pharmaceuticals market consists of the sales of goods such as prescription drugs, over-the-counter medications, generic drugs, and other pharmaceutical products targeting specific therapeutic areas or niche markets. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mid-Size Pharmaceuticals Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mid-size pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mid-size pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mid-size pharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Development Type: In-House; Outsource
  • 2) By Type: Prescription; Over the Counter
  • 3) By Formulation: Tablets; Capsules; Injectables; Sprays; Other Formulations
  • 4) By Application: Cardiovascular Diseases; Pain Management; Diabetes; Cancer; Other Conditions
  • Companies Mentioned: Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co Ltd.; Arkema Inc.; Astellas Pharma Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mid-Size Pharmaceuticals Market Characteristics

3. Mid-Size Pharmaceuticals Market Trends And Strategies

4. Mid-Size Pharmaceuticals Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Mid-Size Pharmaceuticals Market Size and Growth

  • 5.1. Global Mid-Size Pharmaceuticals Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Mid-Size Pharmaceuticals Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Mid-Size Pharmaceuticals Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Mid-Size Pharmaceuticals Market Segmentation

  • 6.1. Global Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • In-House
  • Outsource
  • 6.2. Global Mid-Size Pharmaceuticals Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Prescription
  • Over the Counter
  • 6.3. Global Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tablets
  • Capsules
  • Injectables
  • Sprays
  • Other Formulations
  • 6.4. Global Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cardiovascular Diseases
  • Pain Management
  • Diabetes
  • Cancer
  • Other Conditions

7. Mid-Size Pharmaceuticals Market Regional And Country Analysis

  • 7.1. Global Mid-Size Pharmaceuticals Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Mid-Size Pharmaceuticals Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Mid-Size Pharmaceuticals Market

  • 8.1. Asia-Pacific Mid-Size Pharmaceuticals Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Mid-Size Pharmaceuticals Market

  • 9.1. China Mid-Size Pharmaceuticals Market Overview
  • 9.2. China Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Mid-Size Pharmaceuticals Market

  • 10.1. India Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Mid-Size Pharmaceuticals Market

  • 11.1. Japan Mid-Size Pharmaceuticals Market Overview
  • 11.2. Japan Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Mid-Size Pharmaceuticals Market

  • 12.1. Australia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Mid-Size Pharmaceuticals Market

  • 13.1. Indonesia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Mid-Size Pharmaceuticals Market

  • 14.1. South Korea Mid-Size Pharmaceuticals Market Overview
  • 14.2. South Korea Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Mid-Size Pharmaceuticals Market

  • 15.1. Western Europe Mid-Size Pharmaceuticals Market Overview
  • 15.2. Western Europe Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Mid-Size Pharmaceuticals Market

  • 16.1. UK Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Mid-Size Pharmaceuticals Market

  • 17.1. Germany Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Mid-Size Pharmaceuticals Market

  • 18.1. France Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Mid-Size Pharmaceuticals Market

  • 19.1. Italy Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Mid-Size Pharmaceuticals Market

  • 20.1. Spain Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Mid-Size Pharmaceuticals Market

  • 21.1. Eastern Europe Mid-Size Pharmaceuticals Market Overview
  • 21.2. Eastern Europe Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Mid-Size Pharmaceuticals Market

  • 22.1. Russia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Mid-Size Pharmaceuticals Market

  • 23.1. North America Mid-Size Pharmaceuticals Market Overview
  • 23.2. North America Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Mid-Size Pharmaceuticals Market

  • 24.1. USA Mid-Size Pharmaceuticals Market Overview
  • 24.2. USA Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Mid-Size Pharmaceuticals Market

  • 25.1. Canada Mid-Size Pharmaceuticals Market Overview
  • 25.2. Canada Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Mid-Size Pharmaceuticals Market

  • 26.1. South America Mid-Size Pharmaceuticals Market Overview
  • 26.2. South America Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Mid-Size Pharmaceuticals Market

  • 27.1. Brazil Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Mid-Size Pharmaceuticals Market

  • 28.1. Middle East Mid-Size Pharmaceuticals Market Overview
  • 28.2. Middle East Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Mid-Size Pharmaceuticals Market

  • 29.1. Africa Mid-Size Pharmaceuticals Market Overview
  • 29.2. Africa Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Mid-Size Pharmaceuticals Market Competitive Landscape And Company Profiles

  • 30.1. Mid-Size Pharmaceuticals Market Competitive Landscape
  • 30.2. Mid-Size Pharmaceuticals Market Company Profiles
    • 30.2.1. Baxter International Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Teva Pharmaceutical Industries Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Otsuka Pharmaceutical Co Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Arkema Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Astellas Pharma Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Mid-Size Pharmaceuticals Market Other Major And Innovative Companies

  • 31.1. Daiichi Sankyo Co. Ltd.
  • 31.2. Alexion Pharmaceuticals Inc.
  • 31.3. UCB S.A.
  • 31.4. Sun Pharmaceutical Industries Ltd.
  • 31.5. Eisai Co. Ltd.
  • 31.6. Wuxi AppTec co. Ltd.
  • 31.7. Les Laboratoires Servier S.A.
  • 31.8. Hospira Inc.
  • 31.9. Perrigo Co Plc
  • 31.10. Aurobindo Pharma Limited.
  • 31.11. Cipla Limited
  • 31.12. Hikma Pharmaceuticals
  • 31.13. Endo International plc
  • 31.14. Taisho Pharmaceutical Holdings Co. Ltd.
  • 31.15. BioMarin Pharmaceutical Inc.

32. Global Mid-Size Pharmaceuticals Market Competitive Benchmarking

33. Global Mid-Size Pharmaceuticals Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Mid-Size Pharmaceuticals Market

35. Mid-Size Pharmaceuticals Market Future Outlook and Potential Analysis

  • 35.1 Mid-Size Pharmaceuticals Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Mid-Size Pharmaceuticals Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Mid-Size Pharmaceuticals Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer